Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Criteria the registry did not label

• \<Inclusion Criteria\>
• Newly diagnosed pediatric/adolescent acute lymphomblastic leukemia patient with NCL standard risk that stratifies all 1-4 of following
  • 1 year old ≤ Age \< 10 years old
  • white blood cell at initial diagnosis \< 5x10\^10/L (50,000uL)
  • No testis involvement
  • Satisfaction of following organ functions
• Kidney function (satisfies i or ii) i. Creatinine clearance (or radioisotope-measured GFR) ≥ 70mL/min/1.73m2 ii. Creatinine value according to age/sec satisfies the following:
  • 1 to \< 2 years: Male: 0.6 / Female: 0.6, 2 to \< 6 years: Male: 0.8 / Female: 0.8, 6 to \< 10 years: Male: 1 / Female: 1, 10 to \< 13 years: Male: 1.2 / Female: 1.2, 13 to \< 16 years: Male: 1.5 / Female: 1.4, ≥ 16 years: Male: 1.7 / Female: 1.4 However, subjects who meet the selection criteria within 1 week before registration after receiving appropriate conservative treatment, including fluid therapy, can be registered.
• Liver function i. Direct bilirubin \< 3.0mg/dL
  • \<Exclusion Criteria\>
• Steroid administration within 2 weeks before the registration
• t(9;22) or t(4;11)(q11;q23) or chromosome \< 44 or iAMP21 or t(17;19)/TCF3-HLF
• Newly diagnosed T cell ALL
• One of the following syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or other bone marrow failure syndrome
• Burkitt leukemia/lymphoma
• In the presence of electrocardiographic findings suggesting uncontrolled cardiac dysfunction (e.g., unstable ischemia, symptomatic arrhythmia, congestive heart failure) or congenital long QT syndrome
• When the clinical trial subject(or legal representative) does not consent or is unable to give written consent